Colorectal cancer (CRC) is one of the most common and deadliest forms of cancer worldwide. Molecular subgroups are increasingly relevant for prognosis and therapy. In addition to established markers such as RAS, BRAF and MSI, HER2 is also coming into focus as a therapeutic target. Particularly rare histological variants such as invasive micropapillary carcinoma (IMPC) raise new questions. A recent case report from Japan describes for the first time a patient with HER2-positive colorectal carcinoma and a micropapillary component. This article summarizes the available data and discusses the clinical significance of this constellation.
Autoren
- Tanja Schliebe
Publikation
- InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
You May Also Like
- Neuro-ophthalmology
Visual Snow Syndrome: From the mysterious disorder to effective treatment options
- Platelet and leukocyte abnormalities
Clonal or reactive causes?
- Gonarthrosis and coxarthrosis: update on conservative treatment
Pain relief, targeted movement and relief
- Idiopathic and progressive pulmonary fibrosis (IPF/PPF)
An instrument for clinical use
- Rosacea - multifaceted and multifactorial
Topical and systemic active ingredients: proven and new therapeutic approaches
- Lung cancer
Multidisciplinary teams in oncology
- From diagnostics to personalized therapy
Nuclear medical imaging for Parkinson’s disease
- Psoriasis in difficult localizations: Nail psoriasis